TelyRx Holdings Inc. operates a digital pharmacy platform that connects patients with healthcare services. The company shows strong gross margins at 57.4%, indicating effective cost management; however, it faces significant concerns with negative EBITDA and net margins of -18.2% and -19.7%, respectively, reflecting ongoing operational challenges. Additionally, while the current and quick ratios suggest solid liquidity, the high debt-to-equity ratio of 1.24 raises concerns about leverage. Overall, the company has potential but must address its profitability issues to enhance investor confidence.
Loading financial metrics...
Company posted a loss of $-13.3M over the last year, representing 19.4% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $6.0M over the last year.
Strong gross margin of 56.0% reflects healthy unit economics.
Excellent liquidity with current ratio of 3.5x ensures operational stability.
Strong balance sheet with net cash position provides cushion for growth investments.
Low debt-to-revenue ratio of 19.6% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Pharmaceutical Retailers companies of a similar size
Based on 2026-Q2 (June 30, 2026)